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Group  2  innate  lymphoid  cells  (ILC2)  are  specialized  in type  2 immunity.  ILC2  are  activated  early  in
immune  responses  and,  despite  their  low  abundance,  are  able  to initiate  and  amplify  allergic  inﬂammation
by  orchestrating  other  type  2  immune  cells.  Based  on  recent  discoveries,  the  spectrum  of  ILC2  regulating
factors  has  been  extended.  It is now  well  established  that  not  only  epithelial  cell-derived  innate  cytokines,
but  also  bioactive  lipids  can  regulate  ILC2  activity  and  accumulation.  Additionally,  ILC2 appear  to  be






degree  of cellular  plasticity.  As  ILC2  are  fundamentally  involved  in  the  pathogenesis  of  type  2 diseases,
they  represent  a  promising  therapeutic  target  for allergic  airway  and  skin  diseases.
In  this  review  we  summarize  the  current  knowledge  about  ILC2  biology  in the  allergy  context,  with  a
particular  focus  on the  emerging  role  of  lipid  mediators  in regulating  ILC2  function.
©  2016  The  Author(s).  Published  by  Elsevier  B.V.  on  behalf  of European  Federation  of Immunological
Societies.  This  is  an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/. Introduction
Group 2 innate lymphoid cells (ILC2) have recently emerged
s critical players in the development of allergic inﬂammation.
LC2 belong to a family of cells depending on the transcription
actor Id2 (inhibitor of DNA binding 2), but being independent of
ecombination activating gene 1 and 2 (RAG1/2). This family also
omprises ILC1, ILC3 and NK cells [1–3]. ILCs are predominantly
issue-resident cells [4] lacking antigen-speciﬁc receptors such as
he T and B cell receptors. Instead, ILCs rapidly respond to various
nvironmental stimuli with cytokine production [5,6]. Human ILC2
isplay a distinct cytokine pattern upon stimulation, with prefer-
ntial production of type 2 cytokines such as IL-4, IL-5, IL-9 and
L-13 similarly to Th2 cells, but ILC2 can also produce IL-6, IL-8 and
P10 [7]. As a consequence, ILC2 are capable of mounting an aller-
ic immune response in the absence of Th2 cells [8]. ILC2 decode
ignals detected by epithelial and myeloid cells and convert these
nnate signals into an ampliﬁed immunological reaction against
nvading pathogens or allergens. The epithelial cell-derived fac-
ors include IL-33, thymic stromal lymphopoietin (TSLP) and IL-25
9–11]. Additionally, IL-25 can be produced by eosinophils, mast
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cells and Th2 cells [12]. These three innate cytokines are the best
known activators of ILC2, however, in the absence of TSLP, IL-2 or
IL-7 is additionally required for a potent ILC2 activation [7,13]. Fur-
thermore, IL-1 [14,15] and the TNF superfamily cytokine TL1A
[16] were shown as potent activators of ILC2 cytokine production
(Fig. 1A).
Besides cytokines, lipid mediators are also able to regulate ILC2
function. In particular, leukotriene D4 (LTD4) and prostaglandin D2
(PGD2) appeared as potent activators of ILC2 [17–21]. As negative
regulators of ILC2 function, other lipid mediators like the aspirin-
triggered lipoxin A4 (LXA4) [18], PGI2 [22] and indirectly maresin-1
[23] were demonstrated to attenuate ILC2 responses (Fig. 1A).
Bioactive lipids have been known for long time for their crucial
engagement in maintaining homeostasis and more importantly as
potent mediators of acute inﬂammation [24]. The importance of
lipid mediators is solidly established in the pathology of allergic
inﬂammation [25]. There is a body of evidence describing lipid
mediators as diagnostic markers and they are promising therapeu-
tic targets in type 2 diseases [25,26]. In this mini-review we  will
give a short general update on ILC2 biology with focus on allergic
diseases, and particularly provide a summary of the known roles of
bioactive lipids in shaping ILC2 activity.ion of Immunological Societies. This is an open access article under the CC BY-NC-ND
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Fig. 1. Bioactive lipids regulate ILC2 function. (A) ILC2 produce type 2 cytokines; IL-5, IL-9 and IL-13 after stimulation by IL-33, IL-25, TSLP and IL-2 cytokines. Additionally,
IL-1,  TGF- and TL1A stimulate ILC2 activity, while IFN- and IL-27 inhibit it. PGD2 binds to CRTH2, a Gi-coupled receptor and LTD4 activates CysLT1R, a Gi- or Gq-coupled
receptor. Both lipid mediators, via inducing intracellular Ca2+ mobilization, trigger production of type 2 cytokines on their own and have synergistic effect with IL-25 plus IL-33.
PGI2 binds to IP, a Gs-coupled receptor and elevates cAMP levels intracellularly that results in blocking the IL-33-induced ILC2 cytokine production. Similarly, LXA4 activates
A ion, it 







































tXL,  a Gi-coupled receptor on ILC2, and most likely via inducing ERK phosphorylat
PLA2) enzyme converts cell membrane phospholipids into arachidonic acid, which
ipoxins and the cyclooxygenase (COX)-1/2-metabolite prostaglandins.
. ILC2 development and function
Based on mouse studies, ILC2 develop from the immature
LC2 precursor, which is originated from the common ILC pro-
enitor (CHILP) in the bone marrow [27–29]. Although detailed
nowledge about the origin of human ILC2 is still lacking, it
as recently shown that all human ILC subsets in secondary
ymphoid tissues could be generated from a RORt+ progeni-
or [30]. For the proper development and function of ILC2 the
ranscription factors GATA3 [7,27], ROR [29,31], TCF1 [32], GFI-
 [33], BCl11b [34,35] and ETS1 [36] were demonstrated to be
ndispensable. In mice, ILC2 are readily detected in the blood,
ntestine, lung, spleen, liver, adipose tissue, lymph nodes and
kin [37–42]. In humans, ILC2 were ﬁrst identiﬁed and charac-
erized in the human fetal gut and in nasal polyps of patients
ith chronic rhinosinusitis. However, ILC2 have also been reported
n the blood, lung parenchyma, bronchoalveolar lavage (BAL),
putum, thymus, tonsil and skin [18,43–46]. Mouse and human
LC2 are phenotypically very similar as they are lineage negative
ymphocytes expressing the following combination of cell sur-
ace markers: CD45+CD127+CD161+CD117−/+CD25+CRTH2+ST2+/−
47]. Additionally, mouse ILC2 express Sca1, ICOS and KLRG1 [5].
The innate cytokines IL-33, IL-25 and TSLP are major activators
f ILC2 function and they also induce ILC2 accumulation at sites of
nﬂammation [48–50]. In mice, TGF-1 was recently demonstrated
s an additional epithelial-derived cytokine critical for optimal ILC2
ecruitment and activation in allergic asthma [51]. In response to
timulation, ILC2 release high amounts of IL-4, IL-5, IL-9 and IL-13,
hich initiate and amplify a type 2 immune response [6]. Further-
ore, ILC2 can also be directly stimulated by IL-2 released from
ctivated CD4+ T cells, via synergistic activation together with IL-
3 [52,53]. Notably, ILC2 express MHCII and to some extent CD80
nd CD86 that allow cellular interaction with CD4+ T cells. Thus,
he ILC2-CD4+ T cell crosstalk is mutually beneﬁcial and promotes
he transition between innate to adaptive immunity [52–54].
In addition to soluble cytokines and the MHCII-TCR interac-
ion, a number of receptor-ligand interactions have been shown
o mediate ILC2 activation, including ICOS-ICOSL [55], TL1A-DR3
16,56] OX40L-OX40 [52] and NKp30-ligand B7-H6 [57]. As neg-
tive regulator of ILC2 function the KLRG1-E-cadherin interaction
as demonstrated [58]. Furthermore, IFN- and IL-27 were shown
o restrict ILC2 accumulation and activation [59–61].inhibits IL-33 plus IL-25- and PGD2-stimulated IL-13 release. (B) Phospholipase A2
e precursor of the 5-lipoxygenase (5-LO)-derived leukotrienes, the 15-LO-product
3. ILC2 subsets and plasticity
Single-cell analysis has revealed signiﬁcant transcriptional
heterogeneity among human tonsillar ILC2 [62]. However, the func-
tional consequences of such diversity in an inﬂammatory setting
in the human remain to be determined. In the mouse lung, two
functionally diverse ILC2 subsets were described [50]. One popula-
tion was described as a tissue-resident natural (n)ILC2 expressing
the IL-33 receptor ST2, while the other subset was  characterized
as an inﬂammatory (i)ILC2, accumulating during type 2 inﬂamma-
tion, preferentially responding to IL-25 and expressing IL-17RB and
KLRG1A, but lacking ST2 [50].
In addition to displaying a certain degree of heterogeneity, ILC2
were recently shown to be functionally plastic, adapting to envi-
ronmental ques. In particular, the IL-12/IL-12R-signaling axis was
shown to skew human IL-13-expressing ILC2 towards an IFN- and
T-bet-expressing ILC2 phenotype. Importantly, this IFN-+IL-13+
ILC2 subset was  also identiﬁed in the intestine of patients with
Crohn’s disease [63]. These ﬁndings were complemented by the
description of IL-1 as a critical factor potentiating IL-12 to switch
ILC2 to an ILC1-like phenotype by upregulating T-bet and IL-12R
in ILC2 [14,15]. Interestingly, the IL-12-induced skewing of ILC2
to ILC1 could be reversed by IL-4, indicating that these cells keep
their plasticity [14]. The relevance of these in vitro ﬁndings was
strengthened by a couple of clinical observations. Firstly, chronic
obstructive pulmonary disease (COPD) was  associated with an IL-
12 signature and, by association, consequently ILC1 accumulation.
Secondly, nasal polyps from chronic rhinosinusitis patients dis-
played an IL-4 signature, predicting ILC2 accumulation, which was
indeed seen [14,64].
4. ILC2 in type 2 diseases
4.1. Allergic airway diseases
ILCs have been identiﬁed during homeostatic conditions in sev-
eral types of upper and lower human airway tissues including nasal
mucosa [14,43], lung parenchyma [14,43,44], BAL ﬂuid [41] and
sputum [46]. Histological examinations revealed that lung ILCs can
be detected in small- and medium-sized airways where they, alike
in the skin, seem to interact with mast cells [18]. However, this
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xclude all c-kit− ILCs such as ILC1 and some ILC2. It is therefore of
igh relevance to establish where in the airways the different sub-
opulations of ILCs actually reside during both homeostatic and
nﬂammatory conditions.
All hereto described ILC populations can be found in histo-
ogically healthy human airway tissue. This indicates that ILCs
ight be important for tissue homeostatasis, e.g. via production
f amphiregulin (Areg) [44]. However, ILCs seem to also play crit-
cal roles in type 2 mediated inﬂammation of the human airways.
levated numbers of ILC2 have been detected in airway tissues
btained from patients with asthma [46,65], idiopathic pulmonary
brosis [41], chronic rhinitis [66] and chronic rhinosinusitis with
asal polyps (CRSwNP) [14,43].
Indications of an involvement of ILCs in human asthma exist but
re limited as of today. Bartemes et al. showed that the production
f type 2 cytokines from circulating ILC2 was higher in allergic asth-
atics as compared to healthy controls or allergic rhinitis patients
13], although, these ﬁndings were not conﬁrmed by Barnig et al.
18]. Furthermore, ILC2 were shown to be enriched in asthmatic
AL [67] and in sputum samples of severe asthmatics where they
ere the major source of IL-5 and IL-13 [46]. Similar observations
ere made in severe pediatric asthma [65].
In CRSwNP, ILC2 are enriched as compared to non-affected nasal
issue, particularly in polyps characterized by high eosinophil inﬁl-
ration [14,43]. Co-culture experiments revealed a bidirectional
rosstalk between ILC2 and eosinophils, with ILC2 enhancing the
urvival of eosinophils via IL-5 production, and eosinophils pro-
oting the activity of ILC2 via IL-4 production [14].
The signals driving ILC2 expansion in human airways are largely
nknown but mouse studies have demonstrated several important
echanisms. In mouse models of OVA-, HDM-, papain- or Alternaria
lternata-induced asthma, ILC2 are triggered by epithelial/myeloid-
ell derived soluble factors including IL-25, IL-33, TSLP, TGF-, and
L1A [8,16,29,51,68–70] as well as cell surface receptors such as
COS ligand [55]. Hence, targeting such molecules, e.g. TSLP [71],
ight be a promising strategy to prevent ILC2 activation and the
nitiation of the asthmatic inﬂammation.
.2. Allergic skin diseases
All subsets of ILCs have been identiﬁed in healthy human
kin [45,58,72–74]. Skin ILCs reside predominantly in the der-
is  [45] probably in close proximity to the epidermis, although
hat has so far only been demonstrated in mice [42]. Two sep-
rate mechanisms for a role of ILC2 in skin homeostasis have
een presented. Firstly, it was shown using intravital-multiphoton
icroscopy in mice that ILC2 patrol the dermis and form stable
nteractions with skin-resident mast cells resulting in inhibition
f mast cell function via production of IL-13 [42]. Secondly, in
umans, ILC2 were shown to express transcripts of the epidermal-
rowth factor related molecule amphiregulin (Areg) [58], playing
n important role in wound healing in the lung [44]. Hence, it is pos-
ible that human ILC2 control homeostatic skin integrity through
reg production. Interestingly, the same group also demonstrated
hat ILC2 are homeostatically suppressed by surface expression of
LRG1, interacting with E-cadherin on dermal stromal cells. Loss-
f-function mutations in the human ﬁllagrin gene (FLG) strongly
redisposes for development of atopic dermatitis (AD) through
efects in skin barrier function, including reduced expression of
-cadherin. Indeed, ILC2 were enriched in suction blisters obtained
rom such patients as compared to patients displaying the FLG wild-
ype genotype [75].In established AD, ILC2 are enriched in the dermis and pro-
uce the archetypical cytokines IL-4, IL-5, IL-13 and IL-6 [19,58,72].
s demonstrated in mice [58,72], human dermal ILC2 cytokine-
roduction was driven by IL-25, IL-33 and TSLP [58] and also byy Letters 179 (2016) 36–42
PGD2 [19]. Interestingly, migration of human ILC2 was promoted
by IL-33 [58] and PGD2 [19]. Recently, a novel mechanism of ILC2
activation in AD was  revealed through the discovery that human
ILC2 expressing NKp30 can be activated by the tumor-associated
surface molecule B7-H7, which is upregulated in AD skin [57].
Hence in summary, cytokines, lipid mediators and cell-surface
receptors, which are upregulated in atopic dermatitis, promote the
recruitment and activity of ILC2, which can further contribute to
the inﬂammation via cytokine production.
5. Role of lipid mediators in ILC2 function
Lipids are generally involved in energy metabolism and for-
mation of cellular membranes. However, there is a class of lipid
molecules, termed bioactive lipids, which turned out to be key play-
ers in physiological mechanisms and cell signaling, both in humans
and mice [76]. The most important bioactive lipids are the polyun-
saturated fatty acid (PUFA)-derived eicosanoids, endocannabinoids
and pro-resolving lipid mediators, and the group of sphingolipids
[76]. Eicosanoids are formed from omega-6 PUFA and have been
implicated in several inﬂammatory diseases and cancer [77,78].
In particular, arachidonic acid is the precursor of leukotrienes,
which are lipoxygenase metabolites, and prostaglandins, which
are cyclooxygenase metabolites [77] (Fig. 1B). Eicosanoids can be
rapidly released by mast cells, macrophages, dendritic cells and
eosinophils [24], as well as by endothelial and epithelial cells
[79,80]. Eicosanoids are crucial players in type 2 inﬂammation of
the airways [24,25] and the skin [81].
5.1. Leukotrienes (LTs)
LTs are 5-lipoxygenase (5-LO) products of arachidonic acid and
include two groups; the chemoattractant LTB4 and the cysteinyl
(Cys)LTs: LTC4, LTD4 and LTE4 [82] (Fig. 1B). In the pathophysi-
ology of asthma and other allergic diseases CysLTs, produced by
activated eosinophils, mast cells and alveolar macrophages, play a
central role as potent inﬂammatory lipid mediators [83–85]. CysLTs
are highly active bronchoconstrictors, and can promote airway
smooth muscle hyperplasia and pulmonary edema formation [83].
Notably, CysLTs, in particular LTD4, was  demonstrated to amplify
the antigen-speciﬁc Th2 cell-mediated pulmonary inﬂammation
[86], and more recently, LTD4 turned out to be a potent chemoat-
tractant of Th2 cells [87]. Amongst CysLTs, LTD4 has the highest
afﬁnity to the CysLT1R, which is a Gi- and Gq-coupled receptor,
triggering intracellular Ca2+ mobilization and subsequently rapid
production of IL-4, IL-5 and IL-13 in Th2 cells [87]. LTD4 was
the ﬁrst lipid mediator described to regulate ILC2 function [17]
(Fig. 1A). Mouse Iung and bone marrow ILC2 were also shown
to express CysLT1R at steady state as well as during Alternaria
species challenge [17]. Furthermore, Alternaria species-induced
endogenous LTD4 promoted ILC2 accumulation in the lung in a
CysLT1R-dependent fashion. LTD4 stimulation of ILC2 resulted in
enhanced proliferation and robust production of IL-4, IL-5 and IL-
13 [17]. Later on Xue et al., demonstrated that also human ILC2 can
respond to CysLTs [19].
5.2. Prostaglandins (PGs)
PGs are generated from arachidonic acid via the cyclooxygenase
(COX)-1/2 pathways through two unstable intermediate forms;
PGG2 and PGH2, and by subsequent speciﬁc PG synthase enzymes
[77] (Fig. 1B). The key prostaglandin in driving type 2 inﬂamma-
tion is PGD2, showing elevated levels in the airways of patients
with severe asthma and allergic rhinitis [88–91]. PGD2 is synthe-
sized by hematopoietic PGD2 synthase (HPGDS) predominantly in
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also know as DP2) is selectively expressed by type 2 inﬂammatory
ells like Th2 cells, eosinophils and basophils. Importantly, human
LC2 were identiﬁed based on CRTH2 expression [43]. CRTH2 is
 Gi-coupled receptor similarly to other chemoattractant recep-
ors. CRTH2 mediates activating signals by reducing intracellular
AMP levels and triggering Ca2+ mobilization [90]. Barnig et al.
emonstrated that PGD2 stimulated IL-13 production of human
eripheral blood ILC2 via CRTH2, and PGD2 displayed strong syn-
rgistic effects with IL-25 and IL-33 in the presence of IL-2 [18]
Fig. 1A). A subsequent study further established the importance of
he PGD2-CRTH2 pathway in direct stimulation of human periph-
ral blood and skin ILC2 migration as well as of production of IL-4,
L-5 and IL-13 [19]. Furthermore, PGD2 was shown to potentiate the
L-25 plus IL-33-mediated ILC2 responses, which was partially due
o the CRTH2-ligation-induced upregulation of IL-25 (ST2) and IL-
3 (IL-17RA) receptors [19]. Notably, besides type 2 cytokines, PGD2
lso promoted production of other pro-inﬂammatory cytokines (IL-
, IL-8, IL-9, IL-21, GM-CSF and CSF-1), which was  again further
nhanced by IL-25 and IL-33 stimulation [19]. In addition, the stim-
lating effects of PGD2 were mimicked by IgE-activated mast cell
upernatants in skin ILC2 in a CRTH2-dependent manner [19]. The
GD2-CRTH2 pathway was shown to be a conserved activator of
LC2, as mouse ILC2 function and pulmonary accumulation was
lso driven by PGD2 during helminth-induced type 2 pulmonary
nﬂammation [21]. Consistently, CRTH2-deﬁcient ILC2 displayed
educed responsiveness. However, the lack of CRTH2 expression in
enetically modiﬁed mice did not inﬂuence ILC2 development and
requencies in the lung at steady state [21]. Thus, PGD2 plays a cen-
ral role in ILC2 activation, which further enhances the importance
f ILC2 in orchestrating innate and adaptive immunity.
Unlike PGD2, another prostaglandin, PGI2, was shown to inhibit
uman and mouse ILC2 [22]. The ligation of the PGI2 receptor; IP
eing preferentially a Gs-coupled receptor, leads to an elevation
f intracellular cAMP levels and subsequent activation of protein
inase A (PKA) [93]. Additionally, IP receptor can also be Gi- or
q-coupled [90]. Murine studies suggest that the PGI2-IP signaling
ttenuates allergic inﬂammation as IP-deﬁcient mice had increased
L-4 and IL-5 levels in the lung, and enhanced airway leukocyte
nﬁltration in a short-term OVA model [94]. Recently, the PGI2
nalog cicaprost was shown to reduce IL-33-stimulated produc-
ion of IL-5 and IL-13 in mouse bone marrow-derived ILC2 [22]
Fig. 1A). IP ligation potently blocked ILC2 proliferation and at the
ame time induced apoptosis, which was most probably mediated
ia downregulation of Id2 expression [22]. Additionally, Alternaria
lternata-challenged IP-deﬁcient mice displayed higher IL-5- and
L-13-expressing ILC2 counts in the lung and enhanced inﬁltration
f eosinophils. The ILC2-attenuating role of PGI2 was also demon-
trated in human peripheral blood ILC2 but the effect was more
odest than described in the mouse [22]. Generally, PGI2 analogs
iloprost, cicaprost, treprostinil) are used in humans for pulmonary
ypertension therapy [25]. Yet, in an observational study of patients
ith mild asthma, iloprost did not exert changes in lung function
r methacholine responsiveness [95]. Similarly, an oral PGI2 analog
OP-41483) did not modulate FEV1 or bronchial responsiveness in
table asthmatics [96] questioning the therapeutic value of target-
ng PGI2 in asthma.
.3. Pro-resolving lipid mediators
.3.1. Lipoxins (LXs)
While the early lipid mediators LTs and PGs are involved in
mplifying acute inﬂammation, the subsequent release of lipox-
ns (LXs) promote resolution of the inﬂammation (Fig. 1B). This
rogram of lipid mediator release is played in a sequential order
nd has been termed “lipid mediator class switching” that allows
esolution of the inﬂammatory response [97]. LXs are arachi-y Letters 179 (2016) 36–42 39
donic acid-derived lipid mediators, generated by the 15-LO enzyme
in the inﬂamed lung by bronchial epithelial cells, macrophages
and eosinophils [98]. LXA4 binds to the rather unconventional
ALX receptor that is also called formyl-peptide receptor type
2 (FPR2) as it conveys signals induced by lipid and protein or
short peptide ligands depending on its dimerization status [99].
Based on the encountered ligand, ALX/FPR2 receptor can exert
pro- or anti-inﬂammatory effects. However, LXA4 mediates exclu-
sively anti-inﬂammatory functions [100]. During severe asthma,
LXA4 synthesis and ALX/FPR2 receptor expression is downreg-
ulated [101,102]. Barnig et al. reported the LXA4-AXL pathway
as a potent anti-inﬂammatory regulator of human ILC2 activity
[18]. LXA4 prevented both PGD2- and IL-25 plus IL-33-stimulated
IL-13 production of human peripheral blood ILC2 [18] (Fig. 1A).
Adding physiological relevance to these in vitro ﬁndings, a clini-
cal study reported on a modest improvement of asthma following
LXA4 inhalation after LTC4-induced airway obstruction in asth-
matic patients [103]. More recently, topical application of a stable
LXA4 analog reduced severity and triggered recovery of infantile
eczema in a small exploratory study [104].
5.3.2. Specialized pro-resolving lipid mediators (SPM)
SPMs are derived from omega-3 PUFAs and include structurally
different bioactive lipids such as resolvins, protectins and maresins
[105]. Very recently, maresin-1 (MaR1) was demonstrated to
reduce allergic lung inﬂammation and IL-5, IL-13 expression of
mouse ILC2, with simultaneous induction of amphiregulin [23].
This effect was  however not due to a direct effect of MaR1 on ILC2,
but involved the de novo generation of regulatory T cells (Tregs),
which via TGF- production suppressed ILC2 activity. This work
revealed a multi-cellular regulatory network of MaR1-induced res-
olution of allergic inﬂammation in the lung, which resulted in
limited ILC2 function [23].
Together, bioactive lipids emerge as potent regulators of ILC2
that is now supported by an increasing body of evidence. Acti-
vating lipid mediators are able to stimulate ILC2 function alone
without priming with IL-25, IL-33 or TSLP. However, lipid medi-
ators can have synergistic effects with these innate cytokines,
suggesting engagement of distinct signaling pathways in ILC2
activation. Notably, anti-inﬂammatory lipid mediators do not dis-
tinguish between eicosanoids- or cytokine-induced ILC2 activation,
but suppress ILC2 responsiveness. Hence, ILC2 can be exploited in
multiple ways as therapeutic targets in allergic diseases.
6. Pharmacological targeting of ILC2
ILC2 act as a ﬁrst line of defense as they are tissue-resident and
antigen-independent cells that can be rapidly activated via various
mechanisms instantly leading to initiation of an immune reaction.
In addition, by releasing IL-5 and IL-13, ILC2 can further amplify
allergic inﬂammation, thus ILC2 are key drivers of the pathophysi-
ology in type 2 diseases.
Current guidelines for adult asthma therapy include inhaled or
systemic corticosteroids for attenuating ongoing airway inﬂamma-
tion, and short- or long-acting bronchodilators as well as inhibitors
of the leukotriene or IgE pathways [106]. This treatment regimen
likely affects ILC2 function, as corticosteroids were recently shown
to reduce ILC2 counts in eosinophilic nasal polyp after systemic
corticosteroid treatment [107]. Furthermore, leukotriene receptor
antagonists (montelukast, zaﬁrlukast) can prevent ILC2 activation
by inhibiting the CysLT1R [17].The novel, currently investigated biological treatments for
asthma therapy also frequently affect ILC2-activating- or ILC2-
derived cytokines [108]. For instance the anti-TSLP antibody (AMG
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nﬂammation with reduced levels of blood and sputum eosinophils
n a double-blind, placebo-controlled study [71]. Furthermore, a
umanized monoclonal antibody against the downstream ILC2
ytokine IL-5 (mepolizumab) signiﬁcantly reduced asthma exac-
rbation of patients with severe asthma in two separate clinical
tudies [109,110]. IL-4 and IL-13 also represent attractive targets
108]. Humanized anti-IL-4 antibodies did not show beneﬁcial
ffects in the therapy of severe asthmatics [108], while targeting IL-
3 might be a promising approach [111]. Importantly, dupilumab,
 novel fully human antibody that targets the IL-4R, thereby
nhibiting both IL-4 and IL-13 signaling, improved uncontrolled
oderate-to-severe atopic dermatitis as well as persistent asthma
112,113].
Therapeutic interventions targeting lipid mediators could also
igniﬁcantly affect ILC2 function in allergic diseases. Selective
RTH2 antagonists are currently being evaluated for treating
llergic diseases [114,115]. Two smaller clinical studies reported
mproved late asthmatic responses after allergen challenge and
educed asthma symptom scores [116,117]. Agonists of the
XL/FPR2 receptor also represent a promising therapy for aller-
ic diseases [103,104]. While stable analogs of IP receptor did not
how high therapeutic value for asthmatics [95,96].
. Conclusions and open questions
The relatively recently described ILC2 population appears as cru-
ial player in type 2 inﬂammatory diseases such as airway and skin
llergies. In humans and mice, ILC2 had been identiﬁed in most
xamined tissues during homeostasis. Under allergic inﬂammatory
onditions, ILC2 were found to be accumulated in the airways and
he skin; notably, ILC2 counts were also elevated systemically in
eripheral blood. ILC2 are capable of rapid IL-5 and IL-13 produc-
ion in response to several cytokines and lipid mediators known to
e fundamentally involved in driving type 2 inﬂammation. A num-
er of bioactive lipids have been already identiﬁed to potently affect
LC2 proliferation, accumulation and cytokine production; yet, the
ole of other relevant lipid mediators in ILC2 biology remains to be
lucidated.
As we have recently gained more insights into ILC2-ILC1 plastic-
ty, the obvious question arises, whether there are also conditions
eading to ILC2-ILC3 plasticity, as recently reported in mice. Another
elevant question is, whether the lipid mediators only affect ILC2
unction or can also regulate ILC2 plasticity. In addition, further
tudies are required for investigating if ex-ILC2 retain respon-
iveness to bioactive lipids or lose expression of the respective
eceptors as they lose ability to produce type 2 cytokines. How
ipid mediators control other aspects of ILC2 biology awaits fur-
her investigations and may  provide additional clues in dissecting
he role of ILC2 in type 2 immunity.
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